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 Utility of diuretic response (DR) measured during first 6 hours was tested in 1551 acute 
heart failure patients.  
 DR within the first 6 hours performed as well as DR within the first 48 hours in predicting 
prognosis.  
 The model incorporating serial changes in DR showed additive value with regard to 
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In hospitalized heart failure patients, a poor diuretic response (DR) during the first days of hospital 
admission is associated with worse outcomes. However, it remains unknown whether diuretic response 
in the first hours has similar prognostic value. Moreover, data on the sequential change in DR during 
hospital admission are lacking. 
Methods and Results 
DR (urine output per 40 mg furosemide-equivalent diuretics dose) was measured from 0 to 6 hours 
(DR6), 6 to 48 hours (DR6-48), and 0 to 48 hours (DR48) of the patient’s arrival to the emergency 
department (ED) in 1551 patients with AHF (mean age 78 years old; 56% were male; and 48% were 
de-novo patients with heart failure). Patients with a poor DR within the first 6 hours were older age, 
had worse renal function and were already on diuretic treatment before admission. DR6 was only 
weakly correlated with DR6-48 (Spearman’s rho=0.273; p<0.001). DR6, DR6-48 and DR48 were all 
significantly associated with 60-day mortality independent of other prognostic factors. DR6 and DR48 
showed comparable prognostic ability. However, the model combining DR6 with DR6-48 significantly 
exceeded both DR6 (NRI: 0.249, p=0.032) and DR48 (NRI: 0.287, p=0.025) with regard to 60-day 
mortality prediction.  
Conclusion  












patients with AHF have similar prognostic value, although they were moderately correlated. Changes in 
DR over time provide additional prognostic information.  
 
Keywords: Diuretic resistance; Risk stratification, Prognosis 
 
Introduction 
Intravenous loop diuretics are the cornerstone of treatment of hospitalized heart failure patients1-3. A 
poorer response to diuretic treatment was consistently related to worse outcomes. Poor renal function, 
low systolic blood pressure, ischemic etiology of heart failure, and diabetes are associated with poor 
diuretic response (DR) during 24-96 hours after hospital admission4-6 . Therefore, strategies to improve 
DR in hospitalized heart failure patients are currently being considered. However, some important 
information for these strategies are currently missing. Most importantly, it is yet unknown how long we 
should measure DR in order to use it for risk stratification. In previous studies, the period of DR 
evaluation widely ranged from 24 hours to up to four days according to the definitions used in each 
study. If DR in the first hours has the same prognostic value as diuretic response during 24-96 hours 
after hospital admission, patients with a poor diuretic response can be identified at an earlier stage, 
and therefore treated earlier and more efficiently. However, the clinical significance of DR measured for 
periods shorter than 24 hours has not been elucidated.  
Another point which remains unknown is clinical importance of temporal changes in DR. All previous 












the measurement period. However, no study has investigated the changes in DR over time and its 
prognostic implications.  
REALITY-AHF was a prospective multicenter registry focusing on the association between acute phase 
treatment and prognosis of patients who had a heart failure hospital admission. Enrollment was 
performed from August 2014 to December 2015. Among the 20 participating hospitals, 9 were 
university hospitals and 11 were nonuniversity teaching hospitals. The primary objective of this registry 
was to investigate the prognostic impact of timing of treatment. Therefore, the amount of diuretics 
used and urine output were repetitively evaluated during first 48 hours after patient arrival. This study 
design enable us to evaluate and compare DR evaluated in different time period in terms of prognostic 
predict ability. In the current secondary analysis of REALITY-AHF , we aimed to: 1) evaluate if DR within 
6 hours predicted prognosis as efficiently as DR within 48 hours; 2) test if serial changes in DR over 
time provided additional prognostic information in patients with AHF.  
 
Methods  
Study design and patients 
This was a retrospective post-hoc analysis of the REALITY-AHF, in which 1682 consecutive patients with 
hospitalized AHF were prospectively registered. Enrollment was performed from August 2014 to 
December 2015. Among the 20 participating hospitals, 9 were university hospitals and 11 were 
nonuniversity teaching hospitals. The study design and primary outcomes have been described 












department (ED) within 3 hours from the first evaluation by caregivers and hospitalized through ED. 
The exclusion criteria were: 1) treatment with an intravenous drug started prior to arrival at ED, 2) 
history of heart transplantation, 3) patient on chronic peritoneal dialysis or hemodialysis, 4) acute 
myocarditis, and 5) acute coronary syndrome requiring emergency revascularization. Patients with a 
brain natriuretic peptide (BNP) level < 100 pg/mL or N-terminal-proBNP level < 300 pg/mL at baseline 
and patients with missing BNP and N-terminal-proBNP data were also excluded. All patients were 
enrolled at the ED and baseline data including physical findings, echocardiography, and laboratory data 
were collected at the ED. 
We used prognostic endpoints of 60-day all-cause mortality. All patients were followed up for 1 year 
after discharge and prognostic information was prospectively collected. For those without follow-up 
data in the clinics where the patient was registered, prognostic data was obtained from telephone 
interviews with the medical records department of other medical facilities that managed the patient or 
with the family.  
REALITY-AHF complies with the Declaration of Helsinki and Japanese Ethical Guideline for Medical and 
Health Research Involving Human Subjects. All participants were notified regarding their participation 
in the study and it was explained that they were free to opt out of participation at any time. The study 
protocol was approved by the ethics committee of each participating hospital. Study information 
including the objectives, inclusion and exclusion criteria, and the names of participating hospitals were 
published in the publically available University Hospital Information Network (UMIN-CTR, unique 













Diuretic response  
DR was defined as urine output (in mL) obtained per 40 mg of intravenous furosemide (or equivalent). 
Oral furosemide was converted to half the dose of intravenous furosemide. The doses of oral loop 
diuretics that were considered equivalent to 40 mg intravenous furosemide were 10 mg torasemide 
and 60 mg azosemide. In REALITY-AHF, data on urine output was prospectively collected in pre-defined 
time-windows of 0 to 1.5, 1.5 to 6, 6 to 24, and 24 to 48 hours. However, data on the amount of 
intravenous and oral diuretics used were available only for the time windows of 0 to 6 and 0 to 48 
hours. Therefore, we defined DR based on the urine output for three time windows: from 0 to 6 hours 
(DR6), 6 to 48 hours (DR6-48), and 0 to 48 hours (DR48).  
 
Statistical analysis 
Data are expressed as mean and standard deviation for normally distributed variables, and as median 
with interquartile range (IQR) for non-normally distributed data. Categorical data are expressed as 
numbers and percentages. The relationship between baseline characteristics and tertile groups of each 
DR6, DR6-48, and DR48 was examined using the one-way analysis of variance, Kruskal-Wallis, or 
chi-squared tests, where appropriate. The Cochran-Armitage trend test was used to test for a trend. 
When necessary, variables were transformed for further analyses. Correlations between DRs were 
evaluated using Spearman’s rho.  












baseline (hour 0) variables as predictors to see which variables measurable at baseline can predict DR6; 
2) DR6-48 as the outcome including baseline (hour 0) variables as predictors to see which variables 
measurable at baseline can predict DR 6-48; 3) DR6-48 as the outcome including DR6, heart rate, and 
systolic and diastolic blood pressure at 6 hours instead of these parameters measured at baseline (hour 
0) in order to see how much of DR6-48 can be predicted by DR6 and other data available at the time of 
6 hours after ED arrival; 4) DR48 as the outcome including baseline (hour 0) variables as predictors to 
see how much we can predict DR48 at the time of starting treatment. Multivariable linear regression 
analysis was performed using backward elimination method after including all variables with P value 
below 0.10 in univariate analysis. For prognostic analysis, we selected the following variables as 
preexisting and known prognostic factors: age, history of heart failure, New York Heart Association 
functional class, systolic blood pressure, hemoglobin, serum sodium, blood urea nitrogen, and BNP at 
admission. These variables were used for adjustment in multivariable Cox regression model. To account 
for missing covariate data, multiple imputation was used. We created 20 datasets using a 
chained-equations procedure8, 9. Parameter estimates were obtained for each dataset and 
subsequently combined to produce an integrated result using the method described by Barnard and 
Rubin10. 
To evaluate the additive prognostic value of scores, we constructed the following three models for 
60-day all-cause mortality: DR6 model constructed using DR6 alone; DR6 + DR6-48 model constructed 
incorporating DR6 and DR6-48, and DR48 model which used DR48 alone. Receiver operating 












intervals for the AUCs were obtained with 2000-bootstrap resampling. AUCs were compared using the 
Wald test based on the empirical standard deviation performing 2000-times resampling11. We also 
calculated the continuous (as opposed to the categorical) net-reclassification improvement (NRI) with 
its corresponding 95% confidence interval (CI) to evaluate the incremental predictive ability12. 
Statistical analyses were performed using R version 3.1.2 (R Foundation for Statistical Computing, 
Vienna, Austria; ISBN 3-900051-07-0, URL http://www.R-project.org). A two-sided P value < 0.05 was 
considered statistically significant. 
 
Results 
Patient baseline characteristics for DR  
The study flow chart is shown in Figure 1. The REALITY-AHF cohort comprised of 1682 patients with 
AHF after excluding 80 of 1762 registered patients. Furthermore, we excluded another 22 patients who 
were discharged within two days, 88 patients who were neither treated with intravenous nor with oral 
loop diuretics and 21 patients whose data on diuretics use were missing; thus, 1551 patients remained. 
The mean age was 78 years old, 56% were male, 48% were de-novo patients with heart failure. After 
excluding patients without data on either urine output or diuretic use, data on DR6, DR6-48, and DR48 
were available in 1071, 976, and 1471 patients, respectively. We also excluded patients with extremely 
high (>99th percentile) or low (<1st percentile) values for each DR (n=22 for DR6, n=20 for DR6-48, and 
n=29 for DR48) due to the unreliability of such values, and 1049, 956, and 1452 patients, respectively, 












Baseline characteristics according to tertile groups in DR6, DR6-48, and DR48 are described in Table 1 
and Supplemental Table 1. Overall, poor DR was associated with older age, low blood pressure and 
heart rate, history of heart failure, and being treated with heart failure medication including diuretics, 
beta blocker, and aldosterone blocker. Regarding biomarkers, high white blood cell count, low serum 
albumin, low hemoglobin, low ALT, high creatinine and BUN, high potassium, high glucose, high 
C-reactive protein, and high BNP levels were associated with poor DR.  
The results of univariate linear regression (Supplemental Table 2) and multivariable linear regression 
for each DR showed that older age, and higher serum creatinine and diuretic prescription at baseline 
were associated with poor DR in all three time periods (Table 2). In the model using DR6 and data at 6 
hours, DR6 was the most powerful predictor of DR6-48; however, the final model which consists of all 
of independent predictors including DR6 explained only 8.8% of DR6-48. Supplemental Figure 1 shows 
the correlation of DR6 vs. DR48 and DR6 vs. DR6-48. DR6 was significantly but weakly correlated with 
DR6-48 (Spearman’s rho=0.273, p<0.001), and moderately correlated with DR48 (Spearman’s 
rho=0.544, p<0.001).  
 
Prognostic values of DR6, DR48, and DR6 plus DR6-48  
The overall 60-day follow-up rate was 97.4%, and 120 patients died during each follow-up period. 
Mortality rate for 60 days stratified by tertiles of DR6, DR6-48, and DR48 are shown in Figure 2, and 
poorer DR was significantly associated with higher 60-day mortality in all DRs (p for trend <0.01 for all 












mortality even after adjustment for other prognostic factors when they were individually evaluated 
(Table 3). When both DR6 and DR6-48 were entered into the same Cox model, both were associated 
with 60-day mortality in univariate analysis, but only DR6 was significantly associated with 60-day 
mortality after adjustment for other covariates (Supplemental Table 3). Among 1551 patients, 172 
(11%) were treated with tolvaptan and 627 (40.4%) were treated with carperitide within 48 hours. We 
checked the interaction between these drugs and prognostic value of diuretic response in the Cox 
model, and no significant interaction was found (Supplemental Table 4). 
We grouped patients with available DR6 and DR6-48 into 9 groups according to the tertiles of DR6 and 
DR6-48, and more than half of patients in each tertile of DR6 were categorized into different tertiles of 
DR6-48. Unadjusted mortality tended to increase with decreasing DR6-48 in all tertile groups of DR6 
(Figure 3).  
To evaluate the difference in prognostic predictive ability, we compared the AUCs of the DR6 model, 
DR6 + DR6-48 model, and DR48 model for 60-day mortality (Table 4). There was no statistically 
significant difference in AUC and NRI between DR6 vs. DR48 for 60-day mortality. However, when 
DR6-48 was added to DR6, we found a net 24.9% improvement compared with DR6 and 28.7% 
improvement compared with DR48 in predicting 60-day mortality. We also compared DR6 and DR6-48 
and did not observe significant difference in prognostic predict ability (p=0.768 for AUC comparison; 














In this study, we addressed two questions regarding DR which have remained unanswered in patients 
with AHF. For the first question “does very early DR carry the same predictive value as DR during 
hospital admission?”, we compared DR6 and DR48. DR measured within the first 6 hours of patient 
arrival in ED was significantly associated with 60-day mortality and performed comparable to DR 
measured within 48 hours. For the second question: “Does DR change overtime and what is its 
prognostic implication?”, we compared DR6 and DR6-48. Both entities showed only a notably weak 
association and DR6 poorly predicted DR6-48. Taken together with our finding that DR6-48 provides 
additive prognostic information on top of DR6, this suggests that patients with a poor DR in the first 6 
hours are not necessarily the same patients as those with a poor DR from 6-48 hours, although both 
groups have poorer outcomes.  
 
Prognostic information of diuretic response within 6 hours 
The similar prognostic information of DR6 and DR48 is clinically and scientifically relevant as it enables 
an earlier identification of patients at high risk in the acute setting.  
DR was initially introduced as an objective method to evaluate diuretic resistance, which was defined 
as body weight changes in 4 days per 40 mg of furosemide-equivalent diuretics5, 13. Although 
subsequent studies have consistently shown that poor DR is strongly and independently associated 
with a poor prognosis, very few studies compared the prognostic values between DR measured in 
different time periods. In the ASCEND dataset, DR based on weight change in up to 48 hours of 












correlated with each other, and both were associated with a combined endpoint of death and heart 
failure rehospitalization independent of other covariates. These findings are in line with ours in the 
sense that DR evaluated in a shorter period does not imply a less capable prognostication. Moreover, 
the study found that only DR based on urine output, but not DR in 24 hours based on body weight, was 
an independent predictor of 180-day mortality.  
It is yet unclear whether changes in body weight, net fluid output, or urine output, should be used for 
measurement of DR in terms of better risk stratification, and there are some drawbacks in using urine 
output to determine DR compared to body weight14. Nevertheless, our study results may highlight the 
potential utility of very early DR based on urine output. Moreover, it may be difficult to weigh some 
patients before their condition is stabilized. This study, for the first time, showed the utility of 
short-term DR measurement in the ED setting in terms of risk stratification. Although the prognostic 
capability of DR based on urine or body weight in 6 hours or even within a shorter time period is yet to 
be determined, our study results expand the clinical utility of DR to the ED phase in which very prompt 
risk stratification of the AHF patient is required. Finally, our findings may contribute to better clinical 
study designs through a more accurate and prompt identification of high-risk AHF patients. This is also 
important as recent studies have highlighted the importance of early treatment in AHF patients7, 15, 16.  
 
Variability in diuretic response  
Since we could capture all patients from the beginning of treatment (i.e., arrival at ED), unlike in 












results suggest that considerable inter-patient DR fluctuation occurs over time as less than half of the 
patients remained in the same tertile of DR in the two time periods, and DR6 and DR6-48 were weakly 
associated (rho=0.275, P<0.001). Also, we found that it was difficult to predict DR6-48 even if DR6 was 
taken into consideration. These findings imply that the fluctuation of DR over time is not rare, and this 
fluctuation is not easily predictable. In contrast, findings from PROTECT study showed that DR based on 
weight change in 24 hours and on day 4 were well correlated17. This might be attributable to the 
difference in the definition of DRs, in the sense that body weight might not be as volatile as urine 
volume for reflecting sequential changes in DR. It could also be hypothesized that the majority of 
diuresis occurred mostly within 24 hours. Indeed, our results showed that only DR6 was associated 
with  mortality when they were put together in the same multivariate Cox model. At the same time, 
however, taking both metrics into account was shown to contribute to better prognostic prediction and 
this implies the value of measuring serial changes in DR within 48 hours. Given that DR has been, by 
definition, configured with the assumption that diuretics yield urine output constantly during the 
measurement period, our finding is both scientifically and clinically relevant as it shows that DR is not 
constant but variable and that the fluctuation of DR is prognostic. The main driver of the DR fluctuation 
has yet to be elucidated. It could be the change in responsiveness to diuretic therapy itself. However, it 
could also be the action subsequently taken by physician in response to early DR. 
 
Study Limitations 












cohort were almost all Japanese and generalizability of our results is not clear. Moreover, almost a half 
of all patients were those without history of heart failure taking no heart failure drug at the time of 
admission. Although we checked the impact of history of heart failure on association between DR and 
prognosis, and found no significant interaction (data not shown), this point should be taken into 
account for interpretation of our study results. The protocol of the diuretic therapy was at the 
discretion of the physicians. Some patients were treated with the drugs (e.g. tolvaptan and carperitide) 
that might have affected the association between diuretic response and prognosis. This point should 
also be taken into account as a potential bias for our study results even though our interaction analysis 
results were not statistically significant. We did not have data on DR6 for all patients with DR48 data, as 
not all of patients with DR48 data were treated with furosemide within 6 hours. This might have 
resulted in selection bias and the limited applicability of early DR. By design, this registry enrolled only 
patients hospitalized through ED and the generalizability of our study results to other AHF populations 
hospitalized through non-ED pathways is not clear. Moreover, the generalizability of our study results 
to AHF patients who are not hospitalized and are directly discharged from ED should carefully be 
interpreted. We arbitrarily compared DR measured in two time periods (i.e. 6 and 48 hours); however, 
it is still unclear when and how frequently DR should be measured in order to optimize its prognostic 
value. Testani et al. showed that an equation using serum and urine creatinine concentration measured 
with a spot urine sample obtained one hour after diuretic use can accurately predict urine output18. 
Thus, the applicability of this study result to even early DR prediction is well justified. However, only 












that a larger number of AHF patients are treated with furosemide instead of bumetanide, the 
applicability of the equation in patients treated with furosemide should be confirmed. Moreover, the 
study did not test the equation in the AHF cohort and its prognostic value is unclear. Because the early 
identification of high-risk patients is more crucial in AHF than in the chronic heart failure population, 
DR with urine output or body weight, which has been clearly shown to be a prognostic predictor in a 
number of AHF cohorts, might be a more clinically applicable and reliable risk-stratification tool. Finally, 
accurate measure of urine output in ED setting is not impossible but still challenging, and the feasibility 
of this strategy should be tested in the future studies. 
 
Conclusion  
DR measured during the first 6 hours of ED arrival based on urine output can predict prognosis as 
efficiently as DR measured during the first 48 hours in patients with AHF. DR can change over time, and 
accounting for this change contributes to a better prognostic prediction. Our study results underscore 
the utility of early DR and repetitive DR evaluation in patients with AHF.  
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Figure legends  













Figure 2. Mortality for 60-day according to the tertiles of DR6, DR6-48, and DR48 
 














Figure 3. 60-day mortality, tertiles of DR6, and tertiles of DR6-48 
 
These plots shows the relationship of 60-day and 180-day mortality to the tertiles of DR6 and DR6-48. 













Table 1. Baseline characteristics of patients according to DR6 
Variables 
DR6 






Age (years) 80±11 78±11 76±14 <0.001 
Male gender (%) 196 (55.1) 193 (54.1) 186 (55.4) 0.937 
Arrived by ambulance (%) 226 (63.5) 223 (62.5) 173 (51.5) 0.002 
Systolic blood pressure 
(mmHg) 
151±37 152±37 155±31 0.179 
Diastolic blood pressure 
(mmHg) 
82±24 86±27 89±24 0.002 
Heart rate (bpm) 99±28 98±28 101±29 0.361 
NYHA III or IV  307 (89.5) 290 (83.3) 283 (87.1) 0.056 
Symptom onset time (%) 
   
0.340 
≤ 6 hours 85 (23.9) 85 (23.8) 80 (23.8)   
6 hours - 2 days 94 (26.4) 76 (21.3) 69 (20.5) 
 
> 2 days 177 (49.7) 196 (54.9) 187 (55.7)   
ECG rhythm (%) 
   
0.703 
Sinus 204 (57.5) 197 (55.2) 182 (54.3)   
AF 126 (35.5) 129 (36.1) 131 (39.1) 
 
Others 25 (7.0) 31 (8.7) 22 (6.6)   
LVEF at ED (%) 
   
0.469 
<35% 117 (35.7) 123 (36.6) 111 (35.9)   
35-50% 113 (34.5) 96 (28.6) 92 (29.8) 
 
>50% 98 (29.9) 117 (34.8) 106 (34.3)   
Physical examination (%) 
    
JVD 219 (62.8) 226 (63.7) 214 (64.5) 0.898 
Orthopnea 254 (71.8) 227 (63.6) 216 (64.3) 0.039 
Rale 259 (73.0) 256 (71.7) 232 (69.3) 0.551 
Peripheral edema  251 (70.7) 259 (72.5) 256 (76.2) 0.256 
Pulmonary edema 281 (78.9) 265 (74.2) 260 (77.4) 0.317 
Comorbidities (%) 
    
History of Heart Failure  193 (54.2) 193 (54.1) 140 (41.7) 0.001 
Hypertension  254 (71.3) 233 (65.3) 241 (71.7) 0.113 
Diabetes mellitus 130 (36.5) 144 (40.3) 109 (32.4) 0.098 
COPD 44 (12.4) 30 (8.4) 37 (11.0) 0.218 
Coronary artery disease  118 (33.1) 108 (30.3) 90 (26.8) 0.190 
Medication at admission 













Loop diuretics  206 (57.9) 189 (53.1) 120 (36.3) <0.001 
ACE-I 61 (17.2) 64 (17.9) 54 (16.1) 0.809 
ARB 110 (31.0) 118 (33.1) 105 (31.2) 0.813 
Beta blocker 158 (44.8) 151 (42.5) 122 (36.4) 0.072 
Aldosterone blocker  67 (18.8) 88 (24.6) 57 (17.0) 0.030 
Laboratory data 
    
WBC (/µl) 8500[6200,11400] 7400[5800,9500] 7300[5600,9225] <0.001 
Albumin (g/dL) 3.4±0.6 3.5±0.5 3.6±0.5 <0.001 
Hemoglobin (g/dL)   11.4±2.1 12.0±2.3 12.1±2.4 <0.001 
AST (IU/L) 32[23,50] 30[23,45] 34[25,48] 0.192 
ALT (IU/L) 20[13,35] 21[14,34.50] 25[17,39.25] 0.002 
Creatinine (mg/dL) 1.3[0.9,2.0] 1.2[0.8,1.5] 1.0[0.8,1.3] <0.001 
BUN (mg/dL) 30[22,44] 24[17,31] 21[16,28] <0.001 
Sodium (mEq/L) 139[137,142] 140[137,142] 140[137,142] 0.081 
Potassium (mEq/L) 4.4±0.8 4.4±0.6 4.1±0.6 <0.001 
Glucose (mg/dL) 171±78 174±82 158±73 0.026 
CRP (mg/dL) 0.85[0.30,2.85] 0.59[0.21,1.73] 0.43[0.12,1.46] <0.001 
BNP (pg/mL) 912[494,1641] 702[436,1259] 671[388,1170] <0.001 
Length of hospital stay  
(days) 
16 [10, 28] 16 [10, 25] 16 [11, 24] 0.657 
Type of diuretic 
administered     
Furosemide 355 (99) 356 (99) 334 (99) 0.131 
Azosemide 5 (1) 11 (3) 4 (1.2) 0.742 
Torsaemide 1 (0.3) 3 (0.8) 3 (0.9) 0.542 
 
ACE-I, angiotensin-converting enzyme inhibitor; ALT, aspartate aminotransferase; ARB, angiotensin II receptor 
blocker; AST, alanine aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic 
obstructive pulmonary disease; CRP, C-reactive protein; ED, emergency department; JVD, jugular venous 













Table 2. Multivariate linear regression analysis for DR6, DR6-48, and DR48 
Variables 
Multivariable linear 






Multivariable linear regression for 






MV linear regression for 




































Creatinine  -0.152 -3.91 <0.001 
 
On diuretics  
at baseline  
-0.171 -5.10 <0.001 
 
DR6 0.204 6.336 <0.001 
 
On diuretics  
at baseline  
-0.199 -7.48 <0.001 
Age -0.151 -4.18 <0.001   CRP -0.092 -2.83 0.005   
On diuretics  
at baseline  
-0.164 -5.105 <0.001   Age -0.129 -4.67 <0.001 
On diuretics  
at baseline  
-0.150 -4.13 <0.001 
 
Rale -0.079 -2.40 0.016 
 




0.836 3.18 0.002 
















0.071 2.10 0.036 
      
Hemoglobin -0.078 -2.713 0.006 
Albumin 0.090 2.47 0.014   Age -0.064 -1.98 0.048             BUN -0.077 -2.17 0.029 
BNP -0.073 -2.00 0.046                       Creatinine -0.075 -2.19 0.029 




















Table 3. Univariate and multivariable Cox regression analysis for 60-day and 180-day mortality  
Variables 
60-days mortality 
Univariate Cox Model     
Multivariable Cox Model  
(*full adjustment) 
Hazard ratio 95% CI P value     Hazard ratio 95% CI P value 
Diuretic response in 6 hours 
DR in 6 hours (per 100 mL 
increase)   
0.96 0.94-0.98 0.002     0.95  0.95-0.99 0.021 
Diuretic response in 6-48 hours 
DR in 6-48 hours (per 100 
mL increase) 
0.99 0.98-0.99 0.003     0.99  0.98-0.99 0.045 
Diuretic response in 48 hours 
DR in 48 hours (per 100 mL 
increase) 
0.97 0.96-0.99 <0.001     0.98  0.97-0.99 0.002 
 
CI, confidence interval; DR, diuretic response 
*Adjusted for age, gender, New York Heart Association functional class, systolic blood pressure, heart rate, history of heart failure, history of diabetes, left ventricular 
ejection fraction, prescription of beta blocker, prescription of angiotensin inhibitor or angiotensin II receptor blocker at admission, hemoglobin, serum sodium, serum 












Table 4. Comparison of AUCs of the DR6, DR48, and DR6+DR6-48 models for 60-day and 180-day mortality and NRI  
 
  Updated model for 60-day mortality 
    
DR48 model  
(AUC: 0.66, 95% CI: 0.61-0.72) 
DR6+DR6-48 model  
























(AUC: 0.67, 95% CI: 
0.60-0.73) 
AUC diff: -0.006, P=0.828 AUC diff: +0.03, P=0.697 
NRI: 0.030, 95% CI: -0.218- 0.277, 
P=0.815 
NRI: 0.249, 95% CI: 0.021-0.477, 
P=0.032 
DR48 model 
(AUC: 0.66, 95% CI: 
0.61-0.72) 
 
AUC diff: +0.03, P=0.596 
NRI: 0.287, 95% CI: 0.035-0.538,  
P=0.025 
 
AUC, area under the curve; NRI, net-reclassification improvement 
